Followers | 1122 |
Posts | 64659 |
Boards Moderated | 4 |
Alias Born | 11/11/2010 |
Thursday, April 13, 2017 4:24:07 PM
This business is profitable, and did $3.5 million in revenue for 2016, and with a timely roll-out of the new stores should double, or triple that, in 2017. We believe that this group can grow to 16 stores and produce up to $30 million in annualized revenue by the end of 2018.”The Company is also working on completion of a compounding site in the Southeastern US whose 2016 revenues exceeded $25 million, and a smaller compounder in South Florida that did over $2.5 million in 2016. Both sites are profitable and are expected to become the “hubs” in the network, performing a consolidated fill function, as well as their role in the compounding products arena. “The unique compounding products from these producers will be sold both direct, in the traditional compounding phamacy model, and through the retail storefronts in our network,” explained Leath.When asked about new product lines, Mr. Leath said, “We are also considering an entry into the sterile pharmaceutical area, and have a particular situation under consideration. It is an interesting area, and we think it makes sense, if we can create the right revenue streams, in the best markets. We will advise our investors as we get closer to this decision.”The True Nature Holding, Inc. Advisory Board consists of professionals with subject matter experience in areas specific to the Company's plans and operations. These are "non-operating and non-executive" positions, and as such are not subject to the regulations of Section 16 of the Securities Act. Recently the Company appointed Leo Smith, an investor in the Miami retail operation being acquired, as its lead Advisor in CBD related areas, with a view toward his ability to contribute to the Company's interests in the emerging CBD marketplace. Leath added, “Mr. Smith has existing business interests in the CBD arena, and will expect to have him contribute to our plans in that area over the next few months.
We agree that there is a large and growing marketplace here, and we think we need to carefully evaluate the options before entering the market, and that Leo Smith will help us drive that effort.”The Mission of True Nature Holdings, Inc.To unlock the potential of the compounding pharmacy industry to improve human and animal health, serve unmet patient needs, elevate the dignity of skilled pharmacists, and build shareholder value through the delivery of quality, cost effective, and innovative healthcare products and pharmaceuticals to the world.The Vision of True Nature Holdings, Inc.To become globally recognized for our best practices focused on driving quality, efficiency, and sustainability in the compounding pharmaceutical industry, natural solutions for healthy living, and novel approaches for delivery of these solutions.Statement Under the Private Securities Litigation Reform ActAs contemplated by the provisions of the Safe Harbor section of the Private Securities Litigation Reform Act of 1995, this news release contains forward-looking statements pertaining to future, anticipated, or projected plans, performances, and developments, as well as other statements relating to future operations. All such forward-looking statements are necessarily only estimates or predictions of future results or events and there can be no assurance that actual results or events will not materially differ from expectations. Further information on potential factors that could affect True Nature Holding, Inc. is included in the Company's filings with the Securities and Exchange Commission. We expressly disclaim any intent or obligation to update any forward-looking statements.To learn more about the Company, visit www.
Recent MITI News
- Form 8-K - Current report • Edgar (US Regulatory) • 03/08/2024 05:45:22 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 03/06/2024 07:56:40 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 02/20/2024 02:15:55 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 02/16/2024 06:03:08 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 01/30/2024 09:11:43 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 01/18/2024 09:41:54 PM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 01/17/2024 02:23:03 AM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 01/16/2024 09:30:23 PM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 01/16/2024 05:05:16 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 01/10/2024 09:28:56 PM
- Form 3 - Initial statement of beneficial ownership of securities • Edgar (US Regulatory) • 01/04/2024 10:12:17 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 12/21/2023 08:34:17 PM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 12/20/2023 09:05:06 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 12/13/2023 09:00:12 PM
- Form 10-Q - Quarterly report [Sections 13 or 15(d)] • Edgar (US Regulatory) • 12/13/2023 08:53:10 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 11/09/2023 07:32:18 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 10/19/2023 05:04:40 PM
- Form 10-Q - Quarterly report [Sections 13 or 15(d)] • Edgar (US Regulatory) • 10/04/2023 04:27:09 PM
- Form DEF 14C - Other definitive information statements • Edgar (US Regulatory) • 09/22/2023 06:17:59 PM
- Form PRE 14C - Other preliminary information statements • Edgar (US Regulatory) • 09/01/2023 08:38:54 PM
- Form RW - Registration Withdrawal Request • Edgar (US Regulatory) • 08/29/2023 09:16:57 PM
- Form 10-K - Annual report [Section 13 and 15(d), not S-K Item 405] • Edgar (US Regulatory) • 07/14/2023 08:49:17 PM
FEATURED NanoViricides Reports that the Phase I NV-387 Clinical Trial is Completed Successfully and Data Lock is Expected Soon • May 2, 2024 10:07 AM
ILUS Files Form 10-K and Provides Shareholder Update • ILUS • May 2, 2024 8:52 AM
Avant Technologies Names New CEO Following Acquisition of Healthcare Technology and Data Integration Firm • AVAI • May 2, 2024 8:00 AM
Bantec Engaged in a Letter of Intent to Acquire a Small New Jersey Based Manufacturing Company • BANT • May 1, 2024 10:00 AM
Cannabix Technologies to Deliver Breath Logix Alcohol Screening Device to Australia • BLO • Apr 30, 2024 8:53 AM
Hydromer, Inc. Reports Preliminary Unaudited Financial Results for First Quarter 2024 • HYDI • Apr 29, 2024 9:10 AM